Stock 9926 AKESO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Akeso, Inc. Stock

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:03 2024-05-23 am EDT 		5-day change 1st Jan Change
48.05 HKD +1.59% Intraday chart for Akeso, Inc. -3.32% +3.56%
Apr. 24 Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator MT
Apr. 24 National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer CI

Financials

Sales 2024 * 2.65B 366M 2.86B Sales 2025 * 4.28B 591M 4.61B Capitalization 37.98B 5.25B 40.96B
Net income 2024 * -433M -59.81M -467M Net income 2025 * 260M 35.91M 280M EV / Sales 2024 * 15 x
Net Debt 2024 * 1.71B 237M 1.85B Net Debt 2025 * 420M 58.08M 453M EV / Sales 2025 * 8.97 x
P/E ratio 2024 *
-83.1 x
P/E ratio 2025 *
139 x
Employees 2,778
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.33%
More Fundamentals * Assessed data

Chart Akeso, Inc.

Dynamic Chart

Latest news about Akeso, Inc.

Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator MT
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer CI
Akeso to Raise Over HK$1 Billion Via Share Sale MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5% MT
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023 CI
Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy MT
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials RE
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3% MT
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI CI
Akeso, Inc. Announces Innovative Clinical Development Roadmap CI
Chinese Medical Regulator Accepts Akeso’s Supplemental New Drug Application for Gastric Cancer Therapy MT
Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer CI
More news

Analyst Recommendations on Akeso, Inc.

Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$48.84 From HK$50.14, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$50.14 From HK$46.04, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$46.04 From HK$31.54, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$31.54 From HK$35.81, Keeps at Buy MT
More recommendations

Press releases Akeso, Inc.

Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 AQ
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024 AQ
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference AQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023 AQ
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap PR
More press releases

Quotes and Performance

1 day+1.59%
1 week-3.32%
Current month-0.21%
1 month+2.34%
3 months+5.49%
6 months+1.26%
Current year+3.56%
More quotes

Highs and lows

1 week
46.65
Extreme 46.65
50.30
1 month
45.75
Extreme 45.75
51.00
Current year
37.95
Extreme 37.95
55.00
1 year
30.30
Extreme 30.3
55.00
3 years
11.50
Extreme 11.5
69.90
5 years
11.50
Extreme 11.5
69.90
10 years
11.50
Extreme 11.5
69.90
More quotes

Managers and Directors - Akeso, Inc.

Managers TitleAgeSince
Baiyong Li FOU
 Founder 56 12-03-18
Peng Zhang FOU
 Founder 48 12-03-18
Michelle Xia CEO
 Chief Executive Officer 58 12-03-18
Members of the board TitleAgeSince
Bo Tan BRD
 Director/Board Member 51 20-03-31
Zhongmin Wang FOU
 Founder 55 12-03-18
Yan Xu BRD
 Director/Board Member 61 20-03-31
More insiders

ETFs positioned on Akeso, Inc.

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
1.57% 4 M€ -27.92%
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.44% 2 M€ -14.14%
More ETFs positioned on Akeso, Inc.

Quotes

Date Price Change Volume
24-05-23 48.05 +1.59% 5 263 664
24-05-22 47.3 +0.21% 1,781,202
24-05-21 47.2 -4.16% 3,226,292
24-05-20 49.25 +1.13% 2,510,690
24-05-17 48.7 -2.01% 3,197,436

Delayed Quote Hong Kong S.E., May 23, 2024 at 04:08 am EDT

More quotes

Company Profile

Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
Sector
Biotechnology & Medical Research
Calendar
2024-08-19 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Akeso, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
43.87 CNY
Average target price
55.45 CNY
Spread / Average Target
+26.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AKESO, INC. Stock Akeso, Inc.
+3.56% 5.25B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.99% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.01% 106B
BIONTECH SE Stock BioNTech SE
-3.07% 24.69B
ARGENX SE Stock argenx SE
-0.84% 21.97B
GENMAB A/S Stock Genmab A/S
-4.73% 19.27B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.90% 17.56B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.36% 17.32B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.82% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.05% 12.13B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 9926 Stock